Showing 2131-2140 of 20409 results for "".
Evaluating Race-Neutral Equations in PFTs: Implications for Severe Asthma Care
https://reachmd.com/programs/clinicians-roundtable/evaluating-race-neutral-equations-in-pfts-implications-for-severe-asthma-care/35657/As race-neutral reference equations have become the standard in pulmonary function tests (PFTs), a recent study explored the potential impact of this change on diagnosis and treatment of severe asthma. Join Dr. Isabel Bazan as she dives into the data and explains its implications for patient categorPsoriasis Treatment Redefined: Exploring the Impact of IL-23 Inhibitors
https://reachmd.com/programs/spotlight-psoriasis/psoriasis-treatment-redefined-exploring-the-impact-of-il-23-inhibitors/15836/How do IL-23 inhibitors play a role in treating moderate to severe psoriasis? Join us to find out more.Integrative Treatment of ADHD
https://reachmd.com/programs/clinicians-roundtable/integrative-treatment-of-adhd/760/Join Dr. Ari Tuckman, author of Intergrative Treatment for Adult ADHD: A Practical Easy-to Use Guide for Clinicians, as he discusses the latest integrated treatment model for Attentive Deficit/Hyperactivity Disorder.Identifying the Therapeutic Window in Dravet Syndrome: What the Envision Study Reveals About Early Disease Progression
https://reachmd.com/programs/practical-neurology/program-name/39915/Joseph Sullivan, MD, University of California, San Francisco, CA, reviews findings from the ENVISION natural history study, highlighting early neurodevelopmental changes and their implications for disease-modifying interventions in individuals diagnosed with Dravet syndrome.Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
https://reachmd.com/programs/frontlines-prostate-cancer/prostate-cancer-care-testosterone-therapys-impact-on-biochemical-recurrence/32215/Recent studies have shown that testosterone therapy after radical prostatectomy does not increase—and may even reduce—the risk of biochemical recurrence in prostate cancer patients. Dive into the data and what it might mean for prostate cancer care with Dr. Mohit Khera, Professor in the Scott DepartIVUS Trial
https://reachmd.com/programs/clinicians-roundtable/ivus-trial-1/601/Implications to Patient Care and TreatmentImproving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
https://reachmd.com/programs/project-oncology/improving-diagnosis-of-castleman-disease-the-key-role-of-stromal-cells/26400/Discover how stromal cells can inform new diagnostic methods and therapeutic strategies for Castleman disease.Recognizing Neuroimmune Drivers of Itch in Atopic Dermatitis and Prurigo Nodularis
https://reachmd.com/programs/dermconsult/neuroimmune-itch-atopic-dermatitis-prurigo-nodularis/51038/Disproportionate itch can signal underlying neuroimmune-driven disease in atopic dermatitis and prurigo nodularis, even when visible inflammation appears limited. To learn more about this connection, Dr. Steve Jackson speaks with Dr. Diego Dasilva. Together, they explore how neuroimmune pathways perHow Timing, Titration Speed, and Antiseizure Medication Burden Influence VNS Therapy Outcomes in Epilepsy
https://reachmd.com/programs/practical-neurology/how-timing-titration-speed-and-antiseizure-medication-burden-influence-vns-therapy-outcomes-in-epilepsy/39917/Ryan Verner, PhD, discusses findings from the large, global CORE-VNS study, including how earlier vagus nerve stimulation use and lower baseline antiseizure medication burden were associated with improved clinical response.Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
https://reachmd.com/programs/project-oncology/immune-checkpoint-inhibitors-show-promise-in-patients-with-oncogene-driver-negative-nsclc-who-have-never-smoked/33000/A multi-institutional study presented at ASCO 2025 offers critical new insights into a long-overlooked subset of non-small cell lung cancer (NSCLC) patients: never-smokers without actionable oncogenic drivers. Read about the study’s findings on the key predictors of response to immune checkpoint inh